NCT02521844 2024-10-08
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 1 Active not recruiting